Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Kyndryl Holdings Inc (KD) Price & Performance

Amgen, Inc.Trade
Kyndryl Holdings IncTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Kyndryl Holdings Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while Kyndryl Holdings Inc trades at $13.26 (market cap $2.97B). The key difference: Amgen, Inc. is far larger — about 76× Kyndryl Holdings Inc's market cap, and Amgen, Inc. pays a 2.42% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.

AMGNKD
Market Cap
$225.71B$2.97B
Sector
HealthTechnology
52-Week High
$417.20$33.14
52-Week Low
$271.18$10.59
Enterprise Value
$269.02B$5.79B
Dividend Yield
2.42%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Kyndryl Holdings Inc

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.

Read more on KD